Tiannan Guo received training of clinical medicine (1999-2006) in Tongji Medical College, Huazhong University of Science and Technology, and learned biology (2001-2005) in Wuhan University, before he moved to Singapore for PhD training in cancer proteomics (2008-2012) in the laboratories of Dr. Newman Sze in Nanyang Technological University and Dr. Oi Lian Kon in National Cancer Centre Singapore. In 2012, Tiannan started his postdoctoral training in the laboratory of Dr. Ruedi Aebersold in ETH Zurich. Tiannan moved to Sydney as the Scientific Director of ProCan, group leader of Cancer Proteome, Children’s Medical Research Institute, and the conjoint senior lecturer in The University of Sydney Medical School, in March 2017.

Tiannan joined the Westlake Institute for Advanced Studies, Westlake University in August 2017 as a Tenure Track Assistant Professor, and promoted to Associate Professor with tenure in Jan 2023. He is the director of iMarker lab at Westlake Laboratory in 2020, and an associate faculty member of Research Center for Industries of the Future at Westlake University. He also serves as a council member of Human Proteome Organization (HUPO), the chair of Education and Training Committee, co-chair of HPP Cancer Committee, and a member of Marketing and Outreach Committee, as well as the Secretary General of Chinese Proteome Organization (CN-HUPO). He also serves as an associate editor in Molecular & Cellular Proteomics, an associate editor in Clinical Proteomics, an Executive Advisory Board member in Proteomics and Proteomics Clinical Applications, an advisory board member in Cell Reports Medicine, and an editorial board member in Scientific Data, and an editorial board member in Genomics Proteomics Bioinformatics.

His research focuses on proteomic technological development and applications in precision medicine. He and colleagues developed pressure-cycling technology coupled with SWATH/DIA mass spectrometry to enable effective proteomic analysis of biopsy tissues (Nature Medicine, 2015; Nature Protocols, 2022). His team reported the first proteomic and metabolic profiles of COVDI-19 sera (Cell, 2020), and the first proteomic landscape for COVID-19 autopsies (Cell, 2021a), offering novel approaches and insights to the diagnosis and treatment of COVID-19. With a focus on clinical proteomics technologies (Cell, 2021b), his team is exploring AI-empowered proteomic big data for precision medicine with a focus on thyroid nodule diagnosis (Cell Discovery, 2022).

More in www.guomics.com and www.imarkerlab.com.